Trials / Completed
CompletedNCT02181738
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)
Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 294 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Doxorubicin | Specified dose on specified days |
| DRUG | Vinblastine | Specified dose on specified days |
| DRUG | Dacarbazine | Specified dose on specified days |
Timeline
- Start date
- 2014-08-12
- Primary completion
- 2017-08-31
- Completion
- 2022-12-27
- First posted
- 2014-07-04
- Last updated
- 2023-11-28
- Results posted
- 2018-12-11
Locations
38 sites across 10 countries: United States, Austria, Belgium, Canada, Czechia, Germany, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02181738. Inclusion in this directory is not an endorsement.